+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation



Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation



International Journal of Cardiology 207: 335-340



Left atrial appendage occlusion (LAAO) using the Amplatzer cardiac plug (ACP) is a preventive treatment of atrial fibrillation related thromboembolism. To assess the safety and efficacy of LAAO in patients with chronic kidney disease (CKD). Among the ACP multicentre registry, 1014 patients (75±8yrs) with available renal function were included. Patients with CKD (N=375, CHA2DS2-VASc: 4.9±1.5, HASBLED: 3.4±1.3) were at higher risk than patients without CKD (N=639, CHA2DS2-VASc: 4.2±1.6, HASBLED: 2.9±1.2; p<0.001 for both). Procedural (97%) and occlusion (99%) success were similarly high in all stages of CKD. Peri-procedural major adverse events (MAE) were observed in 5.1% of patients, 0.8% of death, with no difference between patients with and those without CKD (6.1 vs 4.5%, p=0.47). In patients with complete follow-up (1319 patients years), the annual stroke+transient ischaemic attack (TIA) rate was 2.3% and the observed bleeding rate was 2.1% (62 and 60% less than expected, similarly among patients with and those without CKD). Kaplan-Meier analysis showed a lower overall survival (84 vs 96% and 84 vs 93% at 1 and 2yrs. respectively; p<0.001) among patients with an eGFR <30ml/min/1.73m(2). LAAO using the ACP has a similar procedural safety among CKD patients compared to patients with normal renal function. LAAO with ACP offers a dramatic reduction of stroke+TIA rate and of bleeding rate persistent in all stages of CKD, as compared to the expected annual risk.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058059353

Download citation: RISBibTeXText

PMID: 26820363

DOI: 10.1016/j.ijcard.2016.01.003


Related references

The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. Journal of the American College of Cardiology 59(10): 923-929, 2012

Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Clinical Cardiology 40(10): 825-831, 2017

Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Atrial Fibrillation. Interventional Cardiology Clinics 7(2): Xiii-Xxiv, 2018

Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 13(8): 907-914, 2015

Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Nonrheumatic Atrial Fibrillation. Journal of Atrial Fibrillation 6(3): 923, 2013

Transcatheter left atrial appendage occlusion in the prevention of stroke and death in patients with atrial fibrillation. Kardiologia Polska 72(11): 1127-1134, 2014

Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation. Revue Neurologique 171(5): 426-432, 2015

The case of stroke prevention by left atrial appendage occlusion in patients with atrial fibrillation-can we close the file?. Journal of Thoracic Disease 7(10): 1696-1698, 2015

Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: ready for the prime time?. Expert Review of Cardiovascular Therapy 11(12): 1587-1589, 2013

Left Atrial Appendage Occlusion for Secondary Stroke Prevention in Patients with Atrial Fibrillation: Long-Term Results. Cerebrovascular Diseases 47(3-4): 188-195, 2019

Percutaneous Left Atrial Appendage Occlusion for the Prevention of Stroke in Patients with Atrial Fibrillation: Review and Critical Appraisal. Journal of Stroke 20(3): 281-291, 2018

Transcatheter left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: results from the Belgian registry. Eurointervention 13(13): 1603-1611, 2018

Left atrial appendage occlusion for stroke prevention in diabetes mellitus patients with atrial fibrillation: Long-term results. Journal of Diabetes 11(1): 75-82, 2019

Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation 127(24): 2414-2423, 2013

Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared With Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation. American Journal of Cardiology 123(8): 1385, 2019